neoantigen

neoantigen

 [ne″o-an´tĭ-jen]
an intranuclear antigen, e.g., a T antigen, present in cells infected by oncogenic viruses.

neoantigen

/neo·an·ti·gen/ (-an´tĭ-jen) tumor-associated antigen.

neoantigen

[-an′tijən]
Etymology: Gk, neos, new, anti, against, genein, to produce
a new specific antigen that develops in a tumor cell.

neoantigen

a newly acquired and expressed antigen, e.g. a T antigen, present in cells infected by oncogenic viruses.
References in periodicals archive ?
The company has four franchises in various stages of clinical and pre-clinical development: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy.
One of the key topics which will be spoken about at the conference will be Neoantigen in personalized Cancer Immunotherapy.
Specifically, the quality and fitness of neoantigens--tumor-specific mutated peptides on the surface of cancer cells--can influence a patient's response to immune checkpoint inhibitors, and mathematical models of neoantigen fitness can serve as biomarkers for response to immunotherapy, according to investigators of two separate but related studies published in Nature.
NOUS-209 has the potential to be the first neoantigen off-the-shelf cancer vaccine tested in the clinic.
Combination treatments were also observed to induce strong and broad neoantigen specific immune response.
QS-21 Stimulon is currently being used in combination with Agenus' neoantigen vaccine, AutoSynVax, now in a Phase 1 clinical trial in cancer.
Neoantigen formation and clastogenic action of hydrochlorofluorocarbons-123 and perchloroethylene in human MCL-5 cells.
16,19) There is evidence across different tumor types that mutational signatures, neoantigen burden, and expression of other checkpoint inhibitors may predict response to immunotherapies.
Wu, "Personal neoantigen cancer vaccines: the momentum builds," Oncoimmunology, vol.
PhosImmunes groundbreaking neoantigen assets significantly expand Agenuss current efforts, and present exciting near-term opportunities for new products and partnerships, said Garo Armen, Agenuss chairman and chief executive officer, in a statement.
I am focused on methods combining immunohistochemical analysis of the tumour microenvironment, tumour sequencing and neoantigen prediction, and transcriptional signatures of response.
proposed that radiotherapy induces neoantigen formation, which starts a T-cell response months to years after exposure, stimulating the production of transforming growth factor (TGF-b).